Sustainable control of onchocerciasis: ocular pathology in onchocerciasis patients treated annually with ivermectin for 23 years: a cohort study

Méba Banla, Solim Tchalim, Potochoziou K Karabou, Richard G Gantin, Aide I Agba, Abiba Kére-Banla, Gertrud Helling-Giese, Christoph Heuschkel, Hartwig Schulz-Key, Peter T Soboslay, Méba Banla, Solim Tchalim, Potochoziou K Karabou, Richard G Gantin, Aide I Agba, Abiba Kére-Banla, Gertrud Helling-Giese, Christoph Heuschkel, Hartwig Schulz-Key, Peter T Soboslay

Abstract

The evolution and persistence of ocular pathology was assessed in a cohort of Onchocerca volvulus infected patients treated annually with ivermectin for 23 years. Patients were resident in rural Central and Kara Region of Togo and ocular examinations included testing of visual acuity, slit lamp examination of the anterior eye segment and the eye fundus by ophthalmoscopy. Before ivermectin treatment, vivid O.volvulus microfilariae (MF) were observed in the right and left anterior eye chamber in 52% and 42% of patients (n = 82), and dead MF were seen in the right and left cornea in 24% and 15% of cases, respectively. At 23 years post initial treatment (PIT), none of the patients (n = 82) presented with MF in the anterior chamber and cornea. A complete resolution of punctate keratitis (PK) lesions without observable corneal scars was present at 23 years PIT (p<0.0001), and sclerosing keratitits (SK) lessened by half, but mainly in patients with lesions at early stage of evolution. Early-stage iridocyclitis diminished from 42%(rE) and 40%(lE) to 13% (rE+lE)(p<0.0001), but advanced iridocyclitis augmented (p<0.001) at 23 years PIT compared to before ivermectin. Advanced-stage papillitis and chorioretinitis did not regress, while early-stage papillitis present in 28%(rE) and 27%(lE) of patients at before ivermectin regressed to 17%(rE) and 18%(lE), and early-stage chorioretinitis present in 51%(rE+lE) of cases at before ivermectin was observed in 12%(rE) and 13%(lE) at 23 years PIT (p<0.0001). Thus, regular annual ivermectin treatment eliminated and prevented the migration of O. volvulus microfilariae into the anterior eye chamber and cornea; keratitis punctata lesions resolved completely and early-stage sclerosing keratitits and iridocyclitis regressed, whilst advanced lesions of the anterior and posterior eye segment remained progressive. In conclusion, annual ivermectin treatments may prevent the emergence of ocular pathology in those populations still exposed to O.volvulus infection.

Trial registration: www.pactr.org PACTR201303000464219).

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Flowchart showing the recruitment, allocation…
Figure 1. Flowchart showing the recruitment, allocation and follow up of study participants.

References

    1. Sékétéli A, Adeoye G, Eyamba A, Nnoruka E, Drameh P, et al. (2002) The achievements and challenges of the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol (Suppl 1): S15–S28.
    1. Diawara L, Traoré MO, Badji A, Bissan Y, Doumbia K, et al. (2009) Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis 3: e497.
    1. Tekle AH, Elhassan E, Isiyaku S, Amazigo UV, Bush S, et al. (2012) Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control. Parasit Vectors 7: 5–28.
    1. Boatin B (2008) The Onchocerciasis Control Programme in West Africa (OCP). Ann Trop Med Parasitol. 102 (Suppl 1)13–17.
    1. Dadzie Y, Neira M, Hopkins D (2003) Final report of the Conference on the eradicability of Onchocerciasis. Filaria J 2: 1–134.
    1. Greene BM, Taylor HR, Cupp EW, Murphy RP, White AT, et al. (1985) Comparison of ivermectin and diethylcarbamazine in the treatment of onchocerciasis. N Engl J Med 313: 133–138.
    1. Newland HS, White AT, Greene BM, D'Anna SA, Keyvan-Larijani E, et al. (1988) Effect of single-dose ivermectin therapy on human Onchocerca volvulus infection with onchocercal ocular involvement. Br J Ophthalmol 72: 561–569.
    1. Larivière M, Vingtain P, Aziz M, Beauvais B, Weimann D (1985) Double blind study of ivermectin and diethylcarbamazine in african onchocerciasis patients with ocular involvement. Lancet 1: 174–177.
    1. Taylor HR, Murphy RP, Newland HS, White AT, D'Anna SA, et al. (1986) Treatment of onchocerciasis. The ocular effects of ivermectin and diethylcarbamazine. Arch Ophthalmol 104: 863–870.
    1. Dadzie KY, Awadzi K, Bird AC, Schulz-Key H (1989) Ophthalmological results from a placebo controlled comparative 3-dose ivermectin study in the treatment of onchocerciasis. Trop Med Parasitol 40: 355–360.
    1. Dadzie KY, Remme J, De Sole G (1991) Changes in ocular onchocerciasis after two rounds of community-based ivermectin treatment in a holo-endemic onchocerciasis focus. Trans R Soc Trop Med Hyg 85: 267–271.
    1. Baraka OZ, Mahmoud BM, Ali MM, Ali MH, el Sheikh EA, et al. (1995) Ivermectin treatment in severe asymmetric reactive onchodermatitis (sowda) in Sudan. Trans R Soc Trop Med Hyg 89: 312–315.
    1. Darge K, Büttner DW (1995) Ivermectin treatment of hyperreactive onchodermatitis (sowda) in Liberia. Trop Med Parasitol 46: 206–212.
    1. Katabarwa MN, Eyamba A, Nwane P, Enyong P, Yaya S, et al. (2011) Seventeen years of annual distribution of ivermectin has not interrupted onchocerciasis transmission in North Region, Cameroon. Am J Trop Med Hyg 85: 1041–1049.
    1. Umeh RE, Mahmoud AO, Hagan M, Wilson M, Okoye OI, et al. (2010) Prevalence and distribution of ocular onchocerciasis in three ecological zones in Nigeria. Afr J Med Sci 39: 267–275.
    1. Kläger SL, Whitworth JA, Downham MD (1996) Viability and fertility of adult Onchocerca volvulus after 6 years of treatment with ivermectin. Trop Med Int Health 1: 581–589.
    1. Osei-Atweneboana MY, Eng JK, Boakye DA, Gyapong JO, Prichard RK (2007) Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet 369: 2021–2029.
    1. Yaméogo L (2008) Special intervention zones. Ann Trop Med Parasitol. (Suppl 1): 23–24.
    1. Abiose A (1998) Onchocercal eye disease and the impact of Mectizan treatment. Ann Trop Med Parasitol (Suppl 1): S11–S22.
    1. Whitworth JA, Gilbert CE, Mabey DM, Maude GH, Morgan D, et al. (1991) Effects of repeated doses of ivermectin on ocular onchocerciasis: community- based trial in Sierra Leone. Lancet 338: 1000–1003.
    1. Abiose A, Jones BR, Cousens SN, Murdoch I, Cassels-Brown A, et al. (1993) Reduction in incidence of optic nerve disease with annual ivermectin to control onchocerciasis. Lancet 341: 130–134.
    1. Mabey DM, Whitworth JA, Eckstein M, Gilbert CE, Maude GH, et al. (1996) The effects of multiples doses of ivermectin on ocular onchocerciasis. Ophthalmology 103: 1001–1008.
    1. Chippaux JP, Boussinesq M, Fobi G, Lafleur C, Audugé A, et al. (1999) Effect of repeated ivermectin treatments on ocular onchocerciasis: evaluation after six to eight doses. Ophthalmic Epidemiol 6: 229–246.
    1. Rodriguez-Perez MA, Rodriguez MH, Margeli-Pperez HM, Rivas-Alcala AR (1995) Effects of semianual treatments of Ivermectin on the prevalence and intensity of Onchocerca volvulus skin infection, ocular lesions, and intensity of Simulium ochraceum populations in southern Mexico. Am J Trop Medicine Hyg 52: 429–434.
    1. Vieira JC, Cooper PJ, Lovato R, Mancero T, Rivera J, et al. (2007) Impact of long-term treatment of onchocerciasis with ivermectin in Ecuador: potential for elimination of infection. BMC Med 5: 9.
    1. Semba RD, Murphy RP, Newland HS, Awadzi K, Greene BM, et al. (1990) Longitudinal study of lesions of the posterior segment in onchocerciasis. Ophthalmol 97: 1334–41.
    1. De Sole G, Accorsi S, Cresveaux H, Remme J, Walsh F, et al. (1992) Distribution and severity of onchocerciasis in southern Benin, Ghana and Togo. Acta Trop 52: 87–97.
    1. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, et al. (2004) Global data on visual impairment in the year 2002. Bull World Health Organ 82: 844–851.
    1. Bastawrous A, Dean WH, Sherwin JC (2013) Blindness and visual impairment due to age-related cataract in sub-Saharan Africa: a systematic review of recent population-based studies. Br J Ophthalmol 97: 1237–1243.
    1. Balo PK, Wabagira J, Banla M, Kuaovi RK (2000) Specific causes of blindness and vision impairment in a rural area of Southern Togo. J Fr Ophtalmol 23: 459–464.
    1. Ejere H, Schwartz E, Wormald R (2001) Ivermectin for onchocercal eye disease (river blindness). Cochrane Database Systemic Reviews 1: CD002219.
    1. Babalola OE, Ogbuagu FK, Maegga BT, Braide EI, Magimbi C, et al. (2011) African programme for Onchoceriasis control: ophthalmological findings in Bushenyi, Uganda. West Afr J Med 30: 104–109.
    1. Fafowora OF, Osuntokun OO (1997) Age-related eye disease in the elderly members of rural African community. East Afr Med J 74: 435–437.
    1. Adegbehingbe BO, Majengbasan TO (2007) Ocular health status of rural dwellers in south-western Nigeria. Aust J Rural Health 15: 269–272.
    1. Hoerauf A, Specht S, Büttner M, Pfarr K, Mand S, et al. (2008) Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med Microbio Immunol 197: 295–311.
    1. Masud H, Qureshi TQ, Dukley M (2009) Effects of Ivermectin with and without doxycycline on clinical symptoms of onchocerciasis. J Coll Physicians Surg Pak 19: 34–38.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj